A Randomised, Double-Blind, 12-Week, Dose -Ranging Placebo-Controlled Study to Evaluate the Efficcy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
Laufzeit: 01.01.2010 - 31.12.2010
Kurzfassung
This is a double-blind, parallel-group, randomised, proof-of-concept study with 12 weeks of daily oral administration of VB-201 at doses of 20mg/day or 80 mg/day or placebo
